A Phase 2 interventional study of VH4524184 and Matching Placebo in HIV Infections, sponsored by ViiV Healthcare. Completed at 17 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-29.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 176th largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2024, is one of 48 in phase 2, and was the 244th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in Romania, South Africa, Uganda
ViiV Healthcare · Sites in Netherlands
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 85 · Phase 2 53 · Phase 3 68 · Phase 4 18
First in 1994; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 82 across the 210 interventional studies, 328 across the 14 observational. Of the 230 that completed or were terminated, 95 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
6 of the studies in HIV Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07934719ViiV HealthcareMass Balance and Absolute Bioavailability of [14C]-VH4011499 | 2027-02-18 |
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
| NCT07939594ViiV HealthcareAn Evaluation of the Potential for VH4011499 Drug-drug-interactions | 2027-03-12 |
| NCT07525544ViiV HealthcareA Study to Investigate the Safety and PK of VH4770359 in Healthy Participants | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 266 studies in HIV Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy (treatment-naïve). Data from this study will be used to decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the future.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Assessments
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received VH4524184, administered as Dose 1 (low dose) on Day 1, Day 4, and Day 7. On Day 10, participants began open-label standard-of-care (SOC) antiretroviral therapy (ART), which was selected by the investigator and locally sourced. Participants were monitored weekly until Day 38.
Drug: VH4524184 · Drug: Antiretroviral therapy
Participants received VH4524184, administered as Dose 2 (medium dose) on Day 1, Day 4, and Day 7. On Day 10, participants began open-label SOC ART, which was selected by the investigator and locally sourced. Participants were monitored weekly until Day 38.
Drug: VH4524184 · Drug: Antiretroviral therapy
Participants received VH4524184, administered as Dose 3 (high dose) on Day 1, Day 4, and Day 7. On Day 10, participants began open-label SOC ART, which was selected by the investigator and locally sourced. Participants were monitored weekly until Day 38.
Drug: VH4524184 · Drug: Antiretroviral therapy
Participants received matching Placebo to the study intervention on Day 1, Day 4, and Day 7. On Day 10, participants began open-label SOC ART, which was selected by the investigator and locally sourced. Participants were monitored weekly until Day 38.
Drug: Matching Placebo · Drug: Antiretroviral therapy
VH4524184 was administered as tablets orally at Day 1.
VH4524184 Matching Placebo was administered as tablets orally at Day 1.
Antiretroviral therapy was administered as available and as per investigator's recommendation.
Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA)
Plasma samples were collected for the quantitative analysis of plasma HIV-1 RNA. The maximum change from baseline was calculated by determining the largest change from baseline value across all assessment timepoints during the monotherapy period. This is identified by subtracting the lowest post-dose visit value up to Day 10 (inclusive) from the baseline value. The baseline was defined as the most recent pre-dose assessment with a valid, non-missing value, including measurements from any unscheduled visits.
Time frame: At Day 10
Monotherapy and Follow-up: Number of Participants With Any Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An AE can be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Any AEs = occurrence of the symptom regardless of intensity grade.
Time frame: Day 1 to Day 38
Monotherapy and Follow-up: Number of Participants With AEs by Severity
The severity was assessed using The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.1 where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening and Grade 5 = Death.
Time frame: Day 1 to Day 38
Monotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation
Time frame: Day 1 to Day 7
Monotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)
Blood samples were collected at the indicated timepoints.
Time frame: At Baseline (Day 1), Day 2, Day 4, Day 7, Day 10, Day 17, Day 24, Day 31 and Day 38
Monotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameter: Bilirubin
Blood samples were collected at the indicated timepoints.
Time frame: At Baseline (Day 1), Day 2, Day 4, Day 7, Day 10, Day 17, Day 24, Day 31 and Day 38
Monotherapy and Follow-up: Change From Baseline for Liver Panel Laboratory Parameter: Protein
Blood samples were collected at the indicated timepoints.
Time frame: At Baseline (Day 1), Day 2, Day 4, Day 7, Day 10, Day 17, Day 24, Day 31 and Day 38
Monotherapy and Follow-up: Number of Participants With Maximum Toxicity Grade Increase Relative to Baseline in Liver Panel Laboratory Parameters: ALT, AST, ALP, Bilirubin
Liver panel parameters assessed were: ALT, AST, ALP, bilirubin. The parameters were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase is defined as an increase in grade relative to baseline grade.
Time frame: From Baseline (Day 1) and up to Day 38
Monotherapy and Follow-up: Number of Participants With Maximum Toxicity Grade Increase Relative to Baseline in Liver Panel Laboratory Parameters: Protein
Participants are categorized based on changes in their liver panel laboratory parameters (protein) to 'Low,' 'Normal,' or 'High,' unless there is no change in their initial category. Participants whose lab values remain unchanged (e.g., 'High' to 'High') or whose values return to normal are recorded in the 'To Normal or No Change' category. Participants may be counted in both the 'To Low' and 'To High' categories if their values fluctuate between these states. As a result, the percentages may exceed 100% due to dual categorization. Participants with a missing baseline value are assumed to have a normal baseline value.
Time frame: From Baseline (Day 1) and up to Day 38
Monotherapy: Maximum Observed Plasma Drug Concentration (Cmax) of VH4524184
Blood samples were collected at indicated time points for Pharmacokinetic (PK) analysis of VH4524184.
Time frame: At Day 1 and Day 7
Monotherapy: Time to Maximum Observed Plasma Drug Concentration (Tmax) of VH4524184
Blood samples were collected at indicated time points for PK analysis of VH4524184.
Time frame: At Day 1 and Day 7
Monotherapy: Plasma Concentration of VH4524184 at Day 10
Blood samples was collected at indicated time point for PK analysis of VH4524184.
Time frame: At Day 10
Monotherapy: Correlation of VH4524184 Cmax With Maximum Plasma HIV-1 RNA Log 10 Change From Baseline Through Day 10
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value was the latest pre-dose assessment with a non-missing value. Change from baseline is defined as post-dose visit value minus baseline value. Statistical analysis for relationship between PK parameter (Cmax) and PD measure (change from baseline in logarithm to base 10 (log10) values for maximum plasma HIV-1 RNA) were explored using an Emax non-linear mixed-effects model. The model parameters estimated were maximum response (Emax) which is defined as the maximum change (at infinite exposure) and EC50 which defines the PK parameter value that attains 50 percent (%) of the maximal effect
Time frame: From Day 1 to Day 10
Monotherapy: Number of Participants With Treatment-emergent Genotypic Resistance
Plasma samples were collected to assess treatment emergent Genotypic Resistance.
Time frame: At Baseline (Day 1) and Day 10
Monotherapy: Number of Participants With Treatment-emergent Phenotypic Resistance
Plasma samples were collected to assess treatment emergent Phenotypic Resistance.
Time frame: At Baseline (Day 1) and Day 10
Monotherapy: Change From Baseline in Cluster of Differentiation 4 (CD4+) T-cell Counts at Day 10
Blood samples were collected for assessment of T-cells subsets (CD4+ T-cells count) by flow cytometry at Day 10 compared to Baseline.
Time frame: At Day 10 compared to Baseline (Day 1)
| Milestone | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| Started | 6 | 6 | 7 | 3 |
| Completed | 6 | 6 | 7 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| Started | 6 | 6 | 7 | 3 |
| Completed | 6 | 6 | 7 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
Plasma samples were collected for the quantitative analysis of plasma HIV-1 RNA. The maximum change from baseline was calculated by determining the largest change from baseline value across all assessment timepoints during the monotherapy period. This is identified by subtracting the lowest post-dose visit value up to Day 10 (inclusive) from the baseline value. The baseline was defined as the most recent pre-dose assessment with a valid, non-missing value, including measurements from any unscheduled visits.
| Copies per milliliter (copies/mL) | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) | -1.17 ± 0.460 | -2.15 ± 0.254 | -2.31 ± 0.463 | -0.28 ± 0.370 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An AE can be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Any AEs = occurrence of the symptom regardless of intensity grade.
| Participants | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| Monotherapy and Follow-up: Number of Participants With Any Adverse Event (AE) | 4 | 6 | 5 | 2 |
The severity was assessed using The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.1 where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening and Grade 5 = Death.
| Participants | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| Grade 1 | 3 | 4 | 3 | 1 |
| Grade 2 | 1 | 2 | 2 | 1 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 |
| Participants | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| Monotherapy: Number of Participants With AEs Leading to Study Treatment Discontinuation | 0 | 0 | 0 | 0 |
Blood samples were collected at the indicated timepoints.
| International units per liter (IU/L) | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| ALT, Baseline (Day 1) | 25.5 ± 15.35 | 26.0 ± 9.27 | 30.4 ± 20.82 | 21.0 ± 7.21 |
| ALT, Day 2 | 0.0 ± 4.20 | 1.3 ± 2.50 | 4.3 ± 11.70 | 0.0 ± 4.00 |
| ALT, Day 4 | 2.2 ± 4.54 | 0.5 ± 4.42 | 0.0 ± 12.41 | -1.0 ± 1.00 |
| ALT, Day 7 | 0.2 ± 3.25 | -3.5 ± 5.36 | -6.4 ± 14.39 | -1.3 ± 5.86 |
| ALT, Day 10 | 4.5 ± 5.79 | -5.5 ± 5.82 | -6.1 ± 16.95 | 8.3 ± 16.50 |
| ALT, Day 17 | 6.7 ± 15.10 | -7.0 ± 6.24 | -8.0 ± 13.99 | -3.0 ± 8.72 |
| ALT, Day 24 | -1.7 ± 6.15 | 1.2 ± 12.22 | -8.6 ± 14.41 | -4.3 ± 4.51 |
| ALT, Day 31 | -2.8 ± 10.31 | 0.2 ± 7.31 | -10.4 ± 11.84 | -5.0 ± 4.58 |
| ALT, Day 38 | -2.8 ± 8.26 | -2.5 ± 9.16 | -13.0 ± 16.67 | -3.0 ± 5.57 |
| AST, Baseline (Day 1) | 29.7 ± 24.64 | 26.5 ± 11.45 | 25.9 ± 8.76 | 22.3 ± 11.68 |
| AST, Day 2 | -1.3 ± 6.65 | -1.2 ± 4.96 | 2.6 ± 10.06 | 0.0 ± 3.46 |
| AST, Day 4 | 2.2 ± 3.06 | -3.2 ± 9.02 | -2.9 ± 6.12 | 1.3 ± 3.06 |
| AST, Day 7 | -0.3 ± 3.67 | -4.8 ± 6.97 | -4.9 ± 6.57 | -0.7 ± 4.73 |
| AST, Day 10 | 9.7 ± 17.82 | -6.2 ± 8.47 | -4.7 ± 7.45 | 2.0 ± 11.79 |
| AST, Day 17 | 22.0 ± 47.41 | -9.0 ± 5.83 | -5.1 ± 7.36 | -1.3 ± 8.74 |
| AST, Day 24 | 1.2 ± 8.01 | -4.3 ± 6.59 | -3.3 ± 6.73 | -4.0 ± 7.00 |
| AST, Day 31 | -0.8 ± 6.30 | -3.0 ± 4.20 | -2.4 ± 6.45 | -3.0 ± 5.20 |
| AST, Day 38 | -4.7 ± 14.05 | -4.7 ± 5.54 | -6.0 ± 9.36 | 0.3 ± 8.02 |
| ALP, Baseline (Day 1) | 81.3 ± 32.51 | 70.3 ± 15.76 | 72.9 ± 10.06 | 103.7 ± 56.00 |
| ALP, Day 2 | 3.3 ± 9.14 | 2.5 ± 6.69 | 0.6 ± 3.26 | 7.3 ± 13.58 |
| ALP, Day 4 | 2.5 ± 9.18 | -0.2 ± 3.13 | 2.9 ± 5.84 | 13.3 ± 18.01 |
| ALP, Day 7 | 3.7 ± 6.50 | -4.0 ± 3.63 | -2.6 ± 4.72 | 2.7 ± 15.82 |
| ALP, Day 10 | 4.2 ± 3.92 | -1.7 ± 6.53 | 2.1 ± 3.89 | 5.7 ± 13.65 |
| ALP, Day 17 | 4.5 ± 5.09 | 0.0 ± 3.74 | 0.9 ± 6.72 | 8.3 ± 4.93 |
| ALP, Day 24 | 3.2 ± 2.86 | -0.2 ± 5.19 | -0.7 ± 6.80 | -1.3 ± 17.01 |
| ALP, Day 31 | 5.2 ± 3.90 | 0.3 ± 12.60 | 0.1 ± 9.01 | 20.3 ± 14.36 |
| ALP, Day 38 | 4.5 ± 3.51 | 0.2 ± 14.33 | -0.6 ± 5.83 | -3.0 ± 21.17 |
Blood samples were collected at the indicated timepoints.
| Micromoles per liter (μmol/L) | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| Baseline (Day 1) | 8.2935 ± 5.93914 | 5.6145 ± 3.21992 | 5.9117 ± 3.21410 | 8.0370 ± 5.75333 |
| Day 2 | 1.0545 ± 3.03093 | 0.2565 ± 1.32787 | 1.1481 ± 1.75421 | -0.7410 ± 4.86174 |
| Day 4 | 1.4820 ± 5.38437 | 0.8550 ± 2.93204 | 1.6856 ± 3.71694 | -3.2490 ± 5.08132 |
| Day 7 | -1.5105 ± 4.25706 | 2.1660 ± 2.20230 | -0.8306 ± 2.63700 | -1.8813 ± 5.60653 |
| Day 10 | 2.2515 ± 6.11541 | 0.7695 ± 3.53892 | 0.3176 ± 2.28020 | -3.0210 ± 3.16389 |
| Day 17 | 0.7980 ± 7.47774 | 0.1368 ± 3.23863 | 0.4641 ± 3.39097 | 1.7670 ± 4.44052 |
| Day 24 | 1.7100 ± 6.10927 | 0.2280 ± 3.65583 | 1.3436 ± 3.54789 | -0.5130 ± 2.68748 |
| Day 31 | -0.2052 ± 7.41576 | 0.0285 ± 1.40768 | 0.3909 ± 2.62828 | 0.8550 ± 4.42292 |
| Day 38 | 1.7100 ± 5.46665 | -0.1712 ± 3.59512 | 0.2931 ± 1.14163 | -3.1923 ± 3.60425 |
Blood samples were collected at the indicated timepoints.
| Grams per liter | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| Baseline (Day 1) | 76.5 ± 4.55 | 75.5 ± 3.39 | 77.1 ± 5.49 | 70.0 ± 5.57 |
| Day 2 | 2.8 ± 3.60 | 2.2 ± 3.31 | 0.7 ± 3.30 | 5.7 ± 1.53 |
| Day 4 | 4.3 ± 4.37 | 1.5 ± 2.66 | 2.1 ± 2.97 | 2.0 ± 1.00 |
| Day 7 | 2.0 ± 3.63 | -1.3 ± 2.34 | -1.9 ± 3.89 | -1.0 ± 1.00 |
| Day 10 | 2.2 ± 2.40 | -0.7 ± 3.14 | 1.6 ± 2.64 | 0.3 ± 2.08 |
| Day 17 | 1.2 ± 3.25 | 0.4 ± 2.30 | 0.1 ± 5.21 | 7.3 ± 4.16 |
| Day 24 | 0.8 ± 3.06 | 0.3 ± 4.46 | 0.6 ± 4.43 | 2.0 ± 3.00 |
| Day 31 | 0.4 ± 4.56 | -0.2 ± 5.23 | -0.9 ± 3.80 | 8.3 ± 4.51 |
| Day 38 | 0.5 ± 2.26 | -1.3 ± 4.68 | -1.4 ± 4.35 | 2.0 ± 4.58 |
Liver panel parameters assessed were: ALT, AST, ALP, bilirubin. The parameters were graded according to DAIDS grading table Version 2.1 where grades were defined based on numeric criteria as follows Grade 0: participants with missing baseline values; Grade 1: Mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase is defined as an increase in grade relative to baseline grade.
| Participants | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| ALT, Increase to Grade 1 | 0 | 1 | 1 | 0 |
| ALT, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| ALT, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| ALT, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 1 | 0 | 0 | 1 | 0 |
| AST, Increase to Grade 2 | 1 | 0 | 0 | 0 |
| AST, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| AST, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 1 | 1 | 0 | 0 | 0 |
| ALP, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| ALP, Increase to Grade 4 | 0 | 0 | 0 | 0 |
| Bilirubin, Increase to Grade 1 | 0 | 0 | 0 | 0 |
| Bilirubin, Increase to Grade 2 | 0 | 0 | 0 | 0 |
| Bilirubin, Increase to Grade 3 | 0 | 0 | 0 | 0 |
| Bilirubin, Increase to Grade 4 | 0 | 0 | 0 | 0 |
Participants are categorized based on changes in their liver panel laboratory parameters (protein) to 'Low,' 'Normal,' or 'High,' unless there is no change in their initial category. Participants whose lab values remain unchanged (e.g., 'High' to 'High') or whose values return to normal are recorded in the 'To Normal or No Change' category. Participants may be counted in both the 'To Low' and 'To High' categories if their values fluctuate between these states. As a result, the percentages may exceed 100% due to dual categorization. Participants with a missing baseline value are assumed to have a normal baseline value.
| Participants | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| To Low | 0 | 0 | 0 | 0 |
| To Normal or No Change | 4 | 4 | 5 | 2 |
| To High | 2 | 2 | 2 | 1 |
Blood samples were collected at indicated time points for Pharmacokinetic (PK) analysis of VH4524184.
| Nanogram per milliliter (ng/mL) | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 |
|---|---|---|---|
| Day 1 | 1332.57 ± 16.78 | 6173.61 ± 30.71 | 23589.70 ± 32.39 |
| Day 7 | 1488.59 ± 32.06 | 7112.60 ± 16.59 | 23069.92 ± 45.77 |
Blood samples were collected at indicated time points for PK analysis of VH4524184.
| hours | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 |
|---|---|---|---|
| Day 1 | 3.13 (1.0 to 5.0) | 4.00 (2.0 to 5.0) | 2.00 (1.0 to 5.0) |
| Day 7 | 4.00 (0.5 to 5.1) | 4.49 (1.0 to 6.0) | 2.13 (1.0 to 4.0) |
Blood samples was collected at indicated time point for PK analysis of VH4524184.
| ng/mL | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 |
|---|---|---|---|
| Monotherapy: Plasma Concentration of VH4524184 at Day 10 | 127.5 ± 75.59 | 523.5 ± 324.50 | 1328.3 ± 486.99 |
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Baseline value was the latest pre-dose assessment with a non-missing value. Change from baseline is defined as post-dose visit value minus baseline value. Statistical analysis for relationship between PK parameter (Cmax) and PD measure (change from baseline in logarithm to base 10 (log10) values for maximum plasma HIV-1 RNA) were explored using an Emax non-linear mixed-effects model. The model parameters estimated were maximum response (Emax) which is defined as the maximum change (at infinite exposure) and EC50 which defines the PK parameter value that attains 50 percent (%) of the maximal effect
| Log10 copies/mL | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 |
|---|---|---|---|
| Monotherapy: Correlation of VH4524184 Cmax With Maximum Plasma HIV-1 RNA Log 10 Change From Baseline Through Day 10 | -1.17 ± 0.460 | -2.15 ± 0.254 | -2.31 ± 0.463 |
Plasma samples were collected to assess treatment emergent Genotypic Resistance.
| Participants | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 |
|---|---|---|---|
| Day 1 | 0 | 0 | 0 |
| Day 10 | 0 | 0 | 0 |
Plasma samples were collected to assess treatment emergent Phenotypic Resistance.
| Participants | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 |
|---|---|---|---|
| Day 1 | 0 | 0 | 0 |
| Day 10 | 0 | 0 | 0 |
Blood samples were collected for assessment of T-cells subsets (CD4+ T-cells count) by flow cytometry at Day 10 compared to Baseline.
| CD4+ million cells per Liter (10^6/L) | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo |
|---|---|---|---|---|
| Monotherapy: Change From Baseline in Cluster of Differentiation 4 (CD4+) T-cell Counts at Day 10 | 131.333 ± 98.4473 | 68.667 ± 122.1191 | 47.000 ± 45.9093 | 63.667 ± 216.1512 |
Collected over Serious AEs (SAEs) and Non-serious AEs were assessed from Day 1 until the final visit in the Follow-up Period (at Day 38). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VH4524184 Dose 1_Monotherapy | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| VH4524184 Dose 2_Monotherapy | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| VH4524184 Dose 3_Monotherapy | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Placebo_Monotherapy | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| VH4524184 Dose 1_Follow-up | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| VH4524184 Dose 2_Follow-up | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| VH4524184 Dose 3_Follow-up | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Placebo_Follow-up | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Event | VH4524184 Dose 1_Monotherapy | VH4524184 Dose 2_Monotherapy | VH4524184 Dose 3_Monotherapy | Placebo_Monotherapy | VH4524184 Dose 1_Follow-up | VH4524184 Dose 2_Follow-up | VH4524184 Dose 3_Follow-up | Placebo_Follow-up |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/6 | 0/6 | 1/7 | 0/3 | 0/6 | 0/6 | 1/7 | 2/3 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 0/6 | 0/7 | 0/3 | 0/6 | 0/6 | 1/7 | 1/3 |
| DyspepsiaGastrointestinal disorders | 0/6 | 0/6 | 0/7 | 1/3 | 1/6 | 0/6 | 1/7 | 0/3 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 1/7 | 0/3 | 0/6 | 0/6 | 0/7 | 1/3 |
| Upper respiratory tract infectionInfections and infestations | 0/6 | 0/6 | 0/7 | 1/3 | 1/6 | 0/6 | 0/7 | 0/3 |
| Blood pressure increasedInvestigations | 0/6 | 0/6 | 0/7 | 1/3 | 0/6 | 0/6 | 0/7 | 0/3 |
| GastroenteritisInfections and infestations | 0/6 | 0/6 | 0/7 | 0/3 | 0/6 | 1/6 | 0/7 | 1/3 |
| VomitingGastrointestinal disorders | 0/6 | 1/6 | 1/7 | 0/3 | 0/6 | 0/6 | 0/7 | 0/3 |
| FatigueGeneral disorders | 0/6 | 1/6 | 0/7 | 0/3 | 0/6 | 0/6 | 0/7 | 0/3 |
| Influenza like illnessGeneral disorders | 0/6 | 0/6 | 1/7 | 0/3 | 1/6 | 0/6 | 1/7 | 0/3 |
| Age, Continuous(YEARS) | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 34.2 ± 10.61 | 36.7 ± 16.18 | 33.9 ± 12.52 | 29.3 ± 3.79 | 34.1 ± 11.85 |
| Sex: Female, Male(Participants) | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo | Total |
|---|---|---|---|---|---|
| Female | 0 | 2 | 1 | 0 | 3 |
| Male | 6 | 4 | 6 | 3 | 19 |
| Race/Ethnicity, Customized(Participants) | VH4524184 Dose 1 | VH4524184 Dose 2 | VH4524184 Dose 3 | Placebo | Total |
|---|---|---|---|---|---|
| All Other Races | 6 | 6 | 7 | 3 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.viiv-studyregister.com
Ran from Feb 2024 to primary completion in Jun 2024, 4 months.
Results were first posted in Jun 2025, 1 year after primary completion.
Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 4 months is below that.
Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VH4524184